Recomendaciones de manejo farmacológico en COVID-19
During the month of December last 2019, a series of cases of pneumonia were identified in Wuhan (China), which were caused by a new class of coronavirus. This new class of coronavirus has acquired different names, such as: 2019-nCoV named after the World Health Organization (WHO) and SARS-CoV-2, nam...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
2020
|
| Subjects: | |
| Online Access: | https://dialnet.unirioja.es/servlet/oaiart?codigo=7591559 |
| Source: | RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 4, Nº. 2, 2020, pags. 31-39 |
| Tags: |
Add Tag
No Tags: Be the first to tag this record
|
| id |
dialnet-ar-18-ART0001411430
|
|---|---|
| record_format |
dialnet
|
| institution |
Dialnet
|
| collection |
Dialnet AR
|
| source |
RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 4, Nº. 2, 2020, pags. 31-39
|
| language |
Spanish
|
| topic |
Tratamiento
Farmacológico Coronavirus Covid-19 Medicamentos Treatment Pharmacological Coronavirus Covid-19 Medications |
| spellingShingle |
Tratamiento
Farmacológico Coronavirus Covid-19 Medicamentos Treatment Pharmacological Coronavirus Covid-19 Medications Vargas Parraga, Genesis Carolina Chafla Pinduisaca, Franklin Fernando Arelis López Laaz, Susy Correa Quinto, Wilson Pascual Recomendaciones de manejo farmacológico en COVID-19 |
| description |
During the month of December last 2019, a series of cases of pneumonia were identified in Wuhan (China), which were caused by a new class of coronavirus. This new class of coronavirus has acquired different names, such as: 2019-nCoV named after the World Health Organization (WHO) and SARS-CoV-2, name given by the International Committee on Virus Taxonomy. The disease causing this virus has been named 2019-nCoV. As of May 4, 2020, the WHO had registered a total of 1,477,448 confirmed cases worldwide, a total of 86,342 deaths and the virus present in the 54 countries, areas and territories counted for epidemiological purposes. The current reality is that there is no specific pharmacological treatment for COVID-19 treatment whose efficacy and safety have been demonstrated. The fundamental purpose of this study is to capture the pharmacological treatment of COVID 19 that is managed internationally. The research design that was carried out is documentary or bibliographic. The most widely used drugs worldwide for the treatment of COVID 19 are: Hydroxy-chloroquine, Remdesivir, Lopinavir-Ritonavir, Interferon, Oseltamivir, Arbidol, Favipiravir and Vitamin C, among others. It is essential to contribute together as a society in the containment of this virus to save time in the investigation of drugs that guarantee effective treatment and vaccines that allow its prevention, and we hope that these literary reviews will contribute to continue treating in the best possible way to those infected with COVID-19.
|
| format |
Article
|
| author |
Vargas Parraga, Genesis Carolina
Chafla Pinduisaca, Franklin Fernando Arelis López Laaz, Susy Correa Quinto, Wilson Pascual |
| author_facet |
Vargas Parraga, Genesis Carolina
Chafla Pinduisaca, Franklin Fernando Arelis López Laaz, Susy Correa Quinto, Wilson Pascual |
| author_sort |
Vargas Parraga, Genesis Carolina
|
| title |
Recomendaciones de manejo farmacológico en COVID-19
|
| title_short |
Recomendaciones de manejo farmacológico en COVID-19
|
| title_full |
Recomendaciones de manejo farmacológico en COVID-19
|
| title_fullStr |
Recomendaciones de manejo farmacológico en COVID-19
|
| title_full_unstemmed |
Recomendaciones de manejo farmacológico en COVID-19
|
| title_sort |
recomendaciones de manejo farmacológico en covid-19
|
| publishDate |
2020
|
| url |
https://dialnet.unirioja.es/servlet/oaiart?codigo=7591559
|
| _version_ |
1709752306279383040
|
| spelling |
dialnet-ar-18-ART00014114302020-10-14Recomendaciones de manejo farmacológico en COVID-19Vargas Parraga, Genesis CarolinaChafla Pinduisaca, Franklin FernandoArelis López Laaz, SusyCorrea Quinto, Wilson PascualTratamientoFarmacológicoCoronavirusCovid-19MedicamentosTreatmentPharmacologicalCoronavirusCovid-19MedicationsDuring the month of December last 2019, a series of cases of pneumonia were identified in Wuhan (China), which were caused by a new class of coronavirus. This new class of coronavirus has acquired different names, such as: 2019-nCoV named after the World Health Organization (WHO) and SARS-CoV-2, name given by the International Committee on Virus Taxonomy. The disease causing this virus has been named 2019-nCoV. As of May 4, 2020, the WHO had registered a total of 1,477,448 confirmed cases worldwide, a total of 86,342 deaths and the virus present in the 54 countries, areas and territories counted for epidemiological purposes. The current reality is that there is no specific pharmacological treatment for COVID-19 treatment whose efficacy and safety have been demonstrated. The fundamental purpose of this study is to capture the pharmacological treatment of COVID 19 that is managed internationally. The research design that was carried out is documentary or bibliographic. The most widely used drugs worldwide for the treatment of COVID 19 are: Hydroxy-chloroquine, Remdesivir, Lopinavir-Ritonavir, Interferon, Oseltamivir, Arbidol, Favipiravir and Vitamin C, among others. It is essential to contribute together as a society in the containment of this virus to save time in the investigation of drugs that guarantee effective treatment and vaccines that allow its prevention, and we hope that these literary reviews will contribute to continue treating in the best possible way to those infected with COVID-19.Durante el mes de diciembre del pasado 2019 fueron identificadas en Wuhan (China) una serie de casos de neumonía, los cuales estaban siendo originados por una nueva clase de coronavirus. Esta nueva clase de coronavirus ha adquiri-do diferentes denominaciones, tales como: 2019-nCoV nombrado así por la Organización Mundial de la Salud (OMS) y SARS-CoV-2 denominación concedida por el Comité Internacional de Taxonomía de Virus. La enfermedad que causa este virus se ha denominado 2019-nCoV. Hasta el 4 de mayo del 2020 la OMS había registrado en todo el mundo un total de 1.477.448 casos confirmados, un total de 86.342 muertos y el virus presente en los 54 países, zonas y territorios conta-dos con fines epidemiológicos. La realidad actual es que no existe ningún tratamiento farmacológico específico para el tratamiento COVID-19 cuya eficacia y seguridad se encuentre demostrada. El propósito fundamental del presente estudio es plasmar el tratamiento farmacológico de la COVID 19 que se maneja a nivel internacional. El diseño de investigación que se llevó a cabo es de tipo documental o bibliográfico. Los medicamentos más usados en todo el mundo para el trata-miento de la COVID 19 son: Hidroxicloroquina, Remdesivir, Lopinavir-Ritonavir, Interferón, Oseltamivir, Arbidol, Favipiravir y Vitamina C, entre otros. Es fundamental contribuir todos juntos como sociedad en la contención de este virus para ganar tiempo en la investigación de fármacos que garanticen un tratamiento efectivo y de vacunas que permitan su prevención, y esperamos que estas revisiones literarias contribuyan a seguir tratando de la mejor manera posible a los infectados con COVID-19.2020text (article)application/pdfhttps://dialnet.unirioja.es/servlet/oaiart?codigo=7591559(Revista) ISSN 2588-073XRECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 4, Nº. 2, 2020, pags. 31-39spaLICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: https://dialnet.unirioja.es/info/derechosOAI | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: https://dialnet.unirioja.es/info/derechosOAI
|